The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.
The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.
The present disclosure discloses a process for the continuous manufacture of a liquid pharmaceutical composition, the process comprising providing a mixing unit, feeding a therapeutic agent and a liquid vehicle to the mixing unit, operating the latter thereby mixing the agent and the vehicle into a liquid pharmaceutical composition, discharging the composition into a holding unit.
B01F 35/82 - Forming a predetermined ratio of the substances to be mixed by adding a material to be mixed to a mixture in response to a detected feature, e.g. density, radioactivity, consumed power or colour
B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions
The present disclosure discloses a process for the continuous manufacture of a liquid pharmaceutical composition, the process comprising providing a mixing unit, feeding a therapeutic agent and a liquid vehicle to the mixing unit, operating the latter thereby mixing the agent and the vehicle into a liquid pharmaceutical composition, discharging the composition into a holding unit.
The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.
A liquid-transfer adapter operatively interposable between an injector and a vial is provided. The liquid-transfer has an injector engaging portion configured for fluidly coupling to an injector and a vial coupling. The vial coupling includes a spike that has a spike axis and a tip portion configured for piercing a septum of a vial. The tip portion includes a plurality of facets that meet each other at one or more edges and at least one of the one or more edges is sloped with respect to the spike axis. The spike defines a channel extending therethrough in fluid communication with the injector engaging portion. A channel opening is defined in at least one of the facets and disposed without interrupting the edges.
A liquid-transfer adapter operatively interposable between an injector and a vial is provided. The liquid-transfer has an injector engaging portion configured for fluidly coupling to an injector and a vial coupling. The vial coupling includes a spike that has a spike axis and a tip portion configured for piercing a septum of a vial. The tip portion includes a plurality of facets that meet each other at one or more edges and at least one of the one or more edges is sloped with respect to the spike axis. The spike defines a channel extending therethrough in fluid communication with the injector engaging portion. A channel opening is defined in at least one of the facets and disposed without interrupting the edges.
A61B 19/00 - Instruments, implements or accessories for surgery or diagnosis not covered by any of the groups A61B 1/00-A61B 18/00, e.g. for stereotaxis, sterile operation, luxation treatment, wound edge protectors(protective face masks A41D 13/11; surgeons' or patients' gowns or dresses A41D 13/12; devices for carrying-off, for treatment of, or for carrying-over, body liquids A61M 1/00)
A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Pharmaceutical preparations for the treatment of sexual dysfunction; unit-dose self-dispenser applicator for dispensing medicine by individual dose; tandem-dose self-dispenser applicator for holding two medicines to be mixed when dispensed; all for use in the treatment of sexual dysfunction.
16.
Granular compositions of sodium picosulphate and potassium bicarbonate and uses thereof
Compositions are provided that are useful for the preparation of a medicament. The compositions comprise granules having a layer of sodium picosulphate coated on potassium bicarbonate. Additional granules having a layer of magnesium oxide coated on a core of citric acid are also provided. The two types of granules may be combined to obtain mixtures (preferably homogeneous or substantially homogeneous mixtures) of the two types of granules, which are useful, e.g., as pharmaceutical compositions.
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A01N 43/00 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of bloodMaterials for such treatment
B05D 3/00 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
17.
Recombinant FSH including alpha 2,3- and alpha 2,6-sailylation
The present disclosure describes recombinant follicle stimulating hormone (FSH) and methods for the production thereof. The recombinant FSH can include α2,3, α2,6, and, optionally, α2,8 sialylation. The recombinant FSH can be produced in a human cell line such as a PER.C6® cell line.
Compositions are provided that are useful for the preparation of a medicament. The compositions comprise granules having a layer of sodium picosulphate coated on potassium bicarbonate. Additional granules having a layer of magnesium oxide coated on a core of citric acid are also provided. The two types of granules may be combined to obtain mixtures (preferably homogeneous or substantially homogeneous mixtures) of the two types of granules, which are useful, e.g., as pharmaceutical compositions.
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A01N 43/00 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
The present invention relates to oxytocin receptor agonist compounds, pharmaceutical compositions comprising the same, use of such compounds for the manufacture of a medicament for treatment of, inter alia, abdominal pain, irritable bowel syndrome (IBS), autism, erectile dysfunction, female sexual dysfunction, labor induction and maintenance, lactation induction and maintenance, postpartum hemorrhage, Post Traumatic Stress Disorder (PTSD), pain, anxiety and other conditions, as well as to methods for the treatment of such conditions, wherein such compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification:
Compositions, kits, and methods are provided directed to the treatment of prostate cancer using a maintenance dose of degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent.
The present invention relates to novel pharmaceutical compositions suitable for use as foams, notably rectal foams. According to the present invention there is provided a pharmaceutical composition suitable for use as a foam comprising 5 -ASA or a pharmaceutically acceptable salt thereof and a silicone oil. The pharmaceutical composition may remain substantially fluid upon pressurisation, avoiding, for example, significant crystallisation of the active principle. The pharmaceutical composition also provides further physical advantages such as dose reproducibility of the active principle and, if crystallisation does occur, ease of re- suspension. The invention additionally provides a complementary delivery device and/or enhanced foam-forming properties of the pharmaceutical composition.
The present disclosure is directed to gender, age, and dose effects of desmopressin on reducing nocturnal voids, increasing an initial period of undisturbed sleep, and/or reducing nocturnal urine volume.
An antibody that binds strongly to human IL-6/sIL-6R complex and thereby inhibits the transsignaling pathway and characterized by that the antibody essentially does not bind to human IL-6 alone (as such) and to human sIL-6R alone (as such) and thereby essentially does not affect the classical IL-6 signaling pathway.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
26.
TREATMENT OF METASTATIC STAGE PROSTATE CANCER WITH DEGARELIX
The invention provides uses and dosing regimens of a gonadotrophin releasing hormone (GnRH) antagonist for safely and effectively treating androgen-dependent prostate cancer without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
PROCESS FOR THE MANUFACURE OF A PHARMACEUTICAL PRODUCT COMPRISING CITRIC ACID, MAGNESIUM OXIDE, POTASSIUM BICARBONATE AND SODIUM PICOSULFATE, PHARMACEUTICAL COMPOSITION COMPRISING GRANULES OBTAINED BY SUCH PROCESS AND INTERMEDIATE
A process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate and, optionally, saccharin sodium and/or orange flavour; products, intermediate products, and uses thereof.
System for containing and/or preparing an injectable product comprising a liquid and a pharmaceutical product comprising: a cylindrical holder having an inner wall, a proximal end and a distal end; and a piston which is positioned m the cylindrical holder and which is able to slide between an extreme distal position and an extreme proximal position, wherein the piston is provided with two annular low-friction sealing members which are in axial direction separated from each other for maintaining coaxiality independent of an axial position and movement of the piston relative to the cylindrical holder.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient. It addresses means for providing increased shelf-life for said active ingredient in said dosage form.
The invention provides uses and dosing regimens of a gonadotrophin releasing hormone (GnRH) antagonist for safely and effectively treating androgen-dependent prostate cancer without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia- related or cardiovascular side effect.
The present disclosure discloses a process for the continuous manufacture of a liquid pharmaceutical composition, the process comprising providing a mixing unit, feeding a therapeutic agent and a liquid vehicle to the mixing unit, operating the latter thereby mixing the agent and the vehicle into a liquid pharmaceutical composition, discharging the composition into a holding unit.
The invention provides uses and dosing regimens of a gonadotrophin releasing hormone (GnRH) antagonist for safely and effectively treating androgen-dependent prostate cancer without causing a testosterone spike and/or other side effect of Gn RH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
